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Abstract Insulin-degrading enzyme (IDE) is an evolutionarily
conserved neutral thiol metalloprotease expressed in all mam-
malian tissues whose biological role is not well established. IDE
has highly selective substrate specificity. It degrades insulin,
glucagon, atrial natriuretic peptide, transforming growth factor
K but does not act on related hormones and growth factors. The
structural properties determining whether a peptide is an IDE
substrate are essentially unknown. The reported cleavage sites
are not consistent with simple peptide-bond recognition and it
was proposed that IDE recognizes in its substrates some elements
of tertiary structure. We noticed that although IDE substrates
are functionally unrelated, the majority of them share a specific
property, an ability to form under certain conditions amyloid
fibrils. Utilizing the residue pattern recognition procedure, this
study reveals a common motif in the sequences of IDE substrates,
HNHHHPSH, where H is wholly or partly hydrophobic
character, N is small and neutral, P is polar, and S is polar
and/or small amino acid residue. It is proposed that this sequence
motif predetermines a structure recognized by IDE. The
identified motif appears to be essentially the same as the
proposed earlier consensus sequence for amyloid-forming pep-
tides [Turnell and Finch, J. Mol. Biol. 227 (1992) 1205^1223].
The study suggests that IDE may play a role in elimination of
potentially toxic amyloidogenic peptides.
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1. Introduction
The insulin-degrading enzyme (IDE, EC 3.4.24.56) is an
evolutionarily conserved non-lysosomal thiol metalloendopep-
tidase, also referred to as insulinase. IDE is a member of a
newly recognized family of metalloendopeptidases, the pitrily-
sins, which are distinct from classical metalloproteinases in
that they contain an unusual Zn2 binding site [1,2]. This
family also includes Escherichia coli protease III (pitrilysin)
and Drosophila IDE, both of which share a high degree of
homology to mammalian IDEs [3,4] and are distantly related
to IDE mitochondrial [5] and chloroplast [6] processing en-
zymes. IDE is expressed in all mammalian tissues [7], how-
ever, its physiological role remains unknown. It was postu-
lated almost 50 years ago but not ¢rmly established yet that
the enzyme is responsible for proteolysis of insulin, thus ter-
minating its biological action (reviewed in [8]). IDE is devel-
opmentally regulated [7] and is apparently involved in the
morphological and biochemical di¡erentiation of sperm cells
[9] and cultured myoblasts [10].
The remarkable feature of IDE is its highly restricted sub-
strate speci¢city. The enzyme degrades with high a⁄nity sev-
eral polypeptide hormones including insulin [11], atrial natriu-
retic peptide (ANP) [12], transforming growth factor K [13]
and glucagon [14]. On the other hand, IDE does not act on
several other related peptides, such as glucagon-like peptide 1,
glucagon-(19^29), epidermal growth factor, platelet-derived
growth factor, nerve growth factor, and vasoactive intestinal
peptide [15]. Highly similar to ANP in structure, brain natriu-
retic peptide and C-type natriuretic peptide are very poor IDE
substrates [16]. Analysis of cleavage sites in IDE substrates
has revealed no speci¢city for a particular peptide bond,
although some preference for large hydrophobic or basic ami-
no acids on the carboxyl side of the cleavage site has been
noticed [8]. In order to extend the number of potential IDE
substrates, Werlen at al. prepared di¡erent peptides by tryptic
digestion of BSA and CNBr degradation of cytochrome c [17].
Only a few peptides could serve as IDE substrates and again,
as in the case of natural substrates, the speci¢city of IDE was
di⁄cult to categorize. It was demonstrated that metal chela-
tors could inhibit degradation but not binding of the sub-
strates [16,18]. Mutations that abolished catalytic activity of
IDE did not prevent binding of insulin [19]. These results are
consistent with a model whereby IDE ¢rst binds to the sub-
strate recognition site prior to acting as a catalyst. Thus, the
speci¢city of the enzyme is realized at the stage of substrate
binding. Amino acid sequence comparisons have not revealed
any signi¢cant similarity between di¡erent IDE substrates,
suggesting that the enzyme recognizes some unidenti¢ed high-
er order structure. This idea is supported by the observation
that the IDE cleavages are generally grouped on the same side
of substrate molecules when viewing the three-dimensional
structure [20,21]. In this report, it is proposed that IDE
speci¢city is based on recognition of the structural elements
that predetermine the ability of peptides to form amyloid
¢brils. Furthermore, it is demonstrated that IDE substrates
have in their sequence a common motif found previously in
amyloid-forming peptides [22].
2. Hypothesis
Although peptide substrates of IDE are functionally unre-
lated, it is of interest to note that many of them share an
ability to form under certain conditions amyloid ¢brils. In-
deed, amyloid deposits were found at sites of repeated insulin
injections in diabetic patients [23,24]. In the single case where
the amyloid ¢bril protein was extracted and analyzed, it was
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shown to contain intact insulin molecule [24]. Another high-
a⁄nity IDE substrate, ANP, forms amyloids in the atria of
83% of persons aged 80 and over [25,26]. One study demon-
strated that IDE is able to degrade calcitonin [27]. Calcitonin
is a major ¢bril protein in amyloid deposits associated with
medullary carcinoma of the thyroid [28]. We demonstrated
previously that the amyloid L peptide, the principal compo-
nent of amyloid deposits in Alzheimer’s disease brain, could
be speci¢cally cross-linked to IDE in rat brain extracts and
was e⁄ciently degraded by the puri¢ed enzyme [29]. In addi-
tion, insulin, ANP, calcitonin, amyloid L peptide and gluca-
gon can readily form amyloid ¢brils under variety of condi-
tions in vitro (reviewed in [30]). These facts taken together
imply that the peptides having amyloidogenic potential are
somehow recognized by IDE. Thus, it would be not unreason-
able to propose that the amyloidogenic determinant and IDE
substrate recognition motif are similar if not identical.
Although the primary structures of amyloid proteins di¡er
widely, inherent amyloidogenic amino acid sequences prob-
ably exist. This would explain why only some polypeptides
give rise to amyloid ¢brils. Notwithstanding di¡erent solution
structures in the monomer state, amyloidogenic proteins as-
sume a remarkably similar structure when in amyloid ¢brils,
which is a L-pleated sheet conformation [30]. Drawing a par-
allel with the IDE recognition mechanism, it is speculated
that, although IDE substrates do not share common structur-
al properties, they nevertheless may adopt a similar confor-
mation upon binding to the enzyme. Several studies have
demonstrated that polypeptides, IDE substrates, display a
high degree of conformational £exibility and can readily as-
sume L-sheet conformation upon self-association and/or when
bound to lipid. For example, ANP in aqueous solution has a
random structure [31]. However, binding to bilayer vesicles of
acidic phospholipids results in adoption of a highly ordered
structure of L-sheets. A transition to a similar L-structure
occurs upon self-association of the peptide [31]. Amyloid L
peptides (1^28) and (1^42) in solution are mixtures of K-heli-
ces, L-sheets and random coil structures with the conversion
to a L-sheet conformation upon peptide self-association [32].
Another IDE substrate, glucagon, has extended £exible con-
formation in aqueous solution [33] with transition into an all-
L-sheet conformation upon self-aggregation. Unlike these
smaller peptides, insulin, a globular protein with stably folded
elements of secondary structure, dimerizes through L-strands
preexisting in the monomer [34].
As noted above, amyloidogenic peptides do not share sig-
ni¢cant homology at the level of amino acid sequence. Never-
theless, the residue pattern recognition procedure developed
by Turnell [35] allowed him and Finch to satisfactorily align
sequences of di¡erent amyloid-forming peptides [22]. In this
approach, the alignment was performed on the basis of similar
amino acid residue types, e.g. polar versus polar etc., and their
similar relative positions and proportions. The common pat-
terns revealed in this way imply structural rather than simply
sequence homology between peptides. Implementation of
these rules for peptides distant in primary structure, such as
insulin and amyloid L peptide, revealed that the sequence of
residues 21^30 along the insulin B-chain has homology with
residues 16^25 of amyloid L peptide ([22], Table 1). Notably,
the residues within the common pattern, namely residues 24B^
26B of insulin, are involved in insulin dimerization and bind-
ing Congo red dye [22], a speci¢c stain for amyloid deposits.
The residues 17^20 of amyloid L peptide are crucial for the
formation of L-sheet structure and the amyloid properties of
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Table 1
Multiple sequence alignment of IDE peptide substrate fragments
Peptide segments shown are derived from the amino acid sequences of human amyloid L peptide, porcine insulin, human glucagon, horse
cytochrome c, human calcitonin and human amylin. Alignment of sequences was performed according to the residue pattern recognition procedure
[22,35]. Amino acid residues of the same type are marked as (M) wholly or partly hydrophobic; (*) small and neutral; ( :) polar; (+) polar, and/or
small [22]. The residue hydrophobicities are estimated according to Eisenberg and McLachlan [44]. In this method, the hydrophobic character of a
given amino acid residue is not determined by simply a single number, whole residue hydrophobicity, but combines calculations both of the
solvation free energy and of the solvent-accessible surface of each atom of the residue. As a result, amino acid residues such as Arg and Lys, having
both polar and apolar parts, are regarded as partly of hydrophobic character. This is consistent with the experimental data indicating that the
apolar parts of these residues make a signi¢cant contribution to the stability of proteins [44].
4 Amylin binds to but is not degraded by IDE (see text).
ND, not determined.
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the peptide [36]. Remarkably, applying the same procedure it
was possible to align sequence segments of other IDE peptide
substrates ^ glucagon, calcitonin and two cytochrome c frag-
ments (Table 1). Two other IDE substrates, ANP and BSA
fragment (503^518-S-S-543^571), do not ¢t into a common
pattern. The conformation of these peptides is constrained
by the intrachain S-S bond and, therefore, the rules for the
alignment of linear sequences might not be applicable in their
case. Alignment of peptide sequences provided in Table 1
indicates that IDE substrates have in their sequence a com-
mon motif that, at its core, has a consensus sequence of
HNHHHPSH, where H is wholly or partly hydrophobic char-
acter, N is small and neutral, P is polar, and S is polar and/or
small amino acid residue. The distribution of hydrophobic
residues within the motif is characteristic both of amphi-
pathic, K-helical and of L-strand within a L-sheet [22].
That the de¢ned motif serves as a recognition determinant
for IDE is consisted with several experimental data. A¡holter
et al., using a variety of insulin mutants, have established that
the residues B24^B26 which are within the motif (Table 1) are
critical for the high binding a⁄nity of insulin to IDE [37].
Insulin analogues substituted, for example, at position B25
(Phe) with the non-aromatic non-hydrophobic amino acids
Asp or His resulted in respective 16- and 20-fold decreases
in a⁄nity to IDE [37]. From the inhibition of IDE activity
by di¡erent fragments of amyloid L peptide, it appears that
the main interaction site lies in the region of residues 17^24 of
the peptide [38], the same residues that ¢t into the common
pattern (Table 1). Again as in case of insulin, the residues of
amyloid L peptide involved in binding to IDE are crucial for
the amyloid properties of the peptide [36]. Also, competition
studies demonstrated that while glucagon was a potent inhib-
itor of insulin binding to IDE, glucagon-(19^29) and gluca-
gon-like peptide-1 were without e¡ect [15]. Residues 19^29 of
glucagon lie outside the proposed consensus sequence and in
the case of glucagon-like peptide-1, the consensus is disrupted
at several positions (Fig. 1).
While it now seems clear that IDE substrates do share a
common motif, that alone cannot explain fully the substrate
speci¢city of the enzyme. For instance, although insulin, glu-
cagon and amyloid L peptide appear to share a common mo-
tif, the a⁄nity of IDE for these substrates di¡ers signi¢cantly.
While IDE binds to insulin with high a⁄nity (Km = 0.1 WM)
[13], the a⁄nities for glucagon and amyloid L peptide are
relatively low (Km = 5.3 WM and 2.7 WM, respectively
[14,38]). Therefore, it is likely that the residues outside of
proposed motif might participate in modulation of substrate
binding.
3. Conclusions
Analysis of substrate speci¢city of IDE revealed that the
enzyme cleaves peptides, which share an ability to form amy-
loid ¢brils in vivo and/or in vitro. We postulated, therefore,
that the structural features predetermining the amyloidogenic
property of the peptides would serve as the substrate recog-
nition determinant for IDE. A common pattern of residue
types proposed earlier for amyloid-forming peptides [22] was
found in sequence segments of the majority of known IDE
substrates. Remarkably, existing experimental data indicate
that it is the amyloidogenic part of the IDE peptide substrates
that is responsible for their binding to the enzyme [37,38]. The
lack of a speci¢c cleavage motif and negligible homology be-
tween IDE substrates at the level of the amino acid sequence
imply that the higher order structure plays a role in substrate
speci¢city. Precedence for proteolytic enzymes that appear to
recognize a structural motif rather than a substrate-speci¢c
amino acid sequence does exist. Mitochondrial processing
peptidase cleaves the signal sequence from a variety of mito-
chondrial precursor proteins yet there is no obvious cleavage
motif. Recent studies established the importance of a partic-
ular structure in the vicinity of the processing site for signal
peptide recognition by the protease [39]. Analysis of substrate
speci¢city of the endopeptidase magaininase from Xenopus
laevis revealed that the enzyme recognizes a particular sub-
strate conformation [40]. As in the case of IDE, Xenopus
magaininase acts on peptides with negligible amino acid iden-
tity yet experiments with numerous synthetic peptide ana-
logues have established that all the peptidase substrates share
an ability to adopt an amphipathic, K-helical motif [40]. In-
terestingly, Xenopus magaininase has the same inhibition pro-
¢le and molecular mass (about 110 kDa) as IDE [40]. Deter-
mination of the primary sequence of this endopeptidase would
make it possible to establish its relationship with IDE.
The recognition mechanism of IDE proposed here is veri¢-
able. If correct, experiments should demonstrate diminished
a⁄nity to IDE and compromised ability to form amyloid
¢brils of substrate analogues with the substitutions within
the HNHHHPSH motif. The proposed mechanism predicts
that any peptide having amyloidogenic potential and sharing
the recognition motif would bind to the protease. Recently we
tested whether amyloid-forming peptide amylin (Table 1)
could serve as a substrate for IDE. Although this peptide
was found to resist cleavage, it e¡ectively blocked insulin-de-
grading activity of IDE in a competitive manner [41].
Despite numerous studies on IDE, the biological role of the
protease remains to be determined. Cytosolic/peroxisomal lo-
calization of IDE is not consistent with its involvement in
degradation of internalized insulin located within the endo-
somes. The fact that the highest levels of IDE are found in
testes, tongue and brain [7,9], while the major insulin metab-
olizing tissues are liver, kidney and muscle, suggests that IDE
may have other functions beside degrading insulin. The pres-
ence of IDE in all tissues tested and the high evolutionary
conservation of the enzyme imply its involvement in perform-
ing some kind of housekeeping function. We would like to
propose here that IDE might function as a scavenger of po-
tentially toxic protein fragments prone to aggregation and
amyloid formation. As cellular proteins are being constantly
degraded, it is inevitable that some intermediate proteolytic
products with high aggregation potential would appear. In
this respect, it is interesting to note that IDE was found to
be associated with the proteasome [42], a major cellular pro-
teolytic complex, whose generated products range in size from
4 to 25 residues [43].
FEBS 20188 7-5-98
Fig. 1. Alignment of the amino acid sequence of glucagon with that
of glucagon-like peptide 1. The residues that do not ¢t into a com-
mon pattern of the residue types de¢ned in Table 1 are black
boxed.
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Finally, this work may provide a strategy for the design of
speci¢c peptide-based inhibitors of IDE, which will be useful
in elucidating the biological role of the enzyme.
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